Cryosite Ltd

AU:CTE Australia Diagnostics & Research
Market Cap
$36.12 Million
AU$58.33 Million AUD
Market Cap Rank
#31236 Global
#956 in Australia
Share Price
AU$1.20
Change (1 day)
+0.00%
52-Week Range
AU$0.66 - AU$1.30
All Time High
AU$1.30
Categories
Companies in Australia Diagnostics & Research
About

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial … Read more

Cryosite Ltd (CTE) - Net Assets

Latest net assets as of June 2025: AU$2.39 Million AUD

Based on the latest financial reports, Cryosite Ltd (CTE) has net assets worth AU$2.39 Million AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$19.46 Million) and total liabilities (AU$17.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$2.39 Million
% of Total Assets 12.27%
Annual Growth Rate -1.99%
5-Year Change 191.62%
10-Year Change -29.28%
Growth Volatility 103.02

Cryosite Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Cryosite Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Cryosite Ltd (2001–2025)

The table below shows the annual net assets of Cryosite Ltd from 2001 to 2025.

Year Net Assets Change
2025-06-30 AU$2.39 Million +64.87%
2024-06-30 AU$1.45 Million -47.92%
2023-06-30 AU$2.78 Million +49.49%
2022-06-30 AU$1.86 Million +127.16%
2021-06-30 AU$819.23K +428.96%
2020-06-30 AU$154.88K +109.02%
2019-06-30 AU$-1.72 Million -188.30%
2018-06-30 AU$1.94 Million -38.28%
2017-06-30 AU$3.15 Million -6.80%
2016-06-30 AU$3.38 Million -4.69%
2015-06-30 AU$3.54 Million -42.23%
2014-06-30 AU$6.14 Million -2.06%
2013-06-30 AU$6.26 Million +14.30%
2012-06-30 AU$5.48 Million +16.82%
2011-06-30 AU$4.69 Million +7.73%
2010-06-30 AU$4.35 Million +0.33%
2009-06-30 AU$4.34 Million +0.44%
2008-06-30 AU$4.32 Million +15.66%
2007-06-30 AU$3.74 Million +32.80%
2006-06-30 AU$2.81 Million +13.54%
2005-06-30 AU$2.48 Million -18.46%
2004-06-30 AU$3.04 Million +9.71%
2003-06-30 AU$2.77 Million -28.79%
2002-06-30 AU$3.89 Million +0.56%
2001-06-30 AU$3.87 Million --

Equity Component Analysis

This analysis shows how different components contribute to Cryosite Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 82532900.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$3.54 Million 148.10%
Other Comprehensive Income AU$32.00K 1.34%
Total Equity AU$2.39 Million 100.00%

Cryosite Ltd Competitors by Market Cap

The table below lists competitors of Cryosite Ltd ranked by their market capitalization.

Company Market Cap
FABFF
PINK:FABFF
 		$5.03 Million
ELL ENVIRON.HLDGS HD-0001
F:6EL
 		$5.03 Million
Ramp Metals Inc.
V:RAMP
 		$5.03 Million
AGES Industri AB (publ)
ST:AGES-B
 		$5.03 Million
Rig Tenders Tbk
JK:RIGS
 		$5.03 Million
Limitless X Holdings Inc.
OTCQB:LIMX
 		$5.03 Million
Emerge Commerce Ltd
PINK:EMCMF
 		$5.02 Million
Nisun International Enterprise Development Group Co Ltd
NASDAQ:NISN
 		$5.02 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cryosite Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,449,000 to 2,389,000, a change of 940,000 (64.9%).
  • Net income of 1,884,000 contributed positively to equity growth.
  • Dividend payments of 976,000 reduced retained earnings.
  • Other comprehensive income increased equity by 32,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$1.88 Million +78.86%
Dividends Paid AU$976.00K -40.85%
Other Comprehensive Income AU$32.00K +1.34%
Total Change AU$- 64.87%

Book Value vs Market Value Analysis

This analysis compares Cryosite Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 24.41x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 11.47x to 24.41x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-06-30 AU$0.10 AU$1.20 x
2002-06-30 AU$0.10 AU$1.20 x
2003-06-30 AU$0.07 AU$1.20 x
2004-06-30 AU$0.08 AU$1.20 x
2005-06-30 AU$0.06 AU$1.20 x
2006-06-30 AU$0.06 AU$1.20 x
2007-06-30 AU$0.08 AU$1.20 x
2008-06-30 AU$0.09 AU$1.20 x
2009-06-30 AU$0.09 AU$1.20 x
2010-06-30 AU$0.09 AU$1.20 x
2011-06-30 AU$0.10 AU$1.20 x
2012-06-30 AU$0.12 AU$1.20 x
2013-06-30 AU$0.13 AU$1.20 x
2014-06-30 AU$0.13 AU$1.20 x
2015-06-30 AU$0.08 AU$1.20 x
2016-06-30 AU$0.07 AU$1.20 x
2017-06-30 AU$0.07 AU$1.20 x
2018-06-30 AU$0.04 AU$1.20 x
2019-06-30 AU$-0.04 AU$1.20 x
2020-06-30 AU$0.00 AU$1.20 x
2021-06-30 AU$0.02 AU$1.20 x
2022-06-30 AU$0.04 AU$1.20 x
2023-06-30 AU$0.06 AU$1.20 x
2024-06-30 AU$0.03 AU$1.20 x
2025-06-30 AU$0.05 AU$1.20 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cryosite Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 78.86%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 13.35%
  • • Asset Turnover: 0.73x
  • • Equity Multiplier: 8.15x
  • Recent ROE (78.86%) is above the historical average (52.29%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -25.46% -40584.71% 0.00x 1.05x AU$-1.37 Million
2002 -31.47% -265.51% 0.11x 1.12x AU$-1.61 Million
2003 -42.24% -61.49% 0.54x 1.27x AU$-1.45 Million
2004 -31.26% -45.39% 0.48x 1.45x AU$-1.25 Million
2005 -25.03% -20.99% 0.63x 1.88x AU$-868.10K
2006 3.60% 2.47% 0.80x 1.82x AU$-179.96K
2007 24.70% 19.54% 0.74x 1.71x AU$549.15K
2008 10.35% 6.91% 0.89x 1.68x AU$14.95K
2009 0.17% 0.12% 0.84x 1.69x AU$-426.78K
2010 0.11% 0.08% 0.78x 1.76x AU$-430.86K
2011 7.13% 5.20% 0.75x 1.84x AU$-134.83K
2012 18.66% 13.18% 0.79x 1.78x AU$474.41K
2013 19.95% 14.71% 0.75x 1.81x AU$623.54K
2014 8.24% 5.51% 0.82x 1.82x AU$-107.91K
2015 12.84% 4.74% 1.05x 2.57x AU$100.73K
2016 8.95% 3.01% 1.04x 2.86x AU$-35.36K
2017 -4.51% -2.44% 0.59x 3.12x AU$-456.97K
2018 -12.59% -4.17% 0.76x 3.98x AU$-439.04K
2019 0.00% -7.14% 0.34x 0.00x AU$-393.55K
2020 955.72% 16.59% 0.38x 151.75x AU$1.46 Million
2021 79.66% 6.51% 0.46x 26.85x AU$570.65K
2022 73.29% 11.60% 0.55x 11.55x AU$1.18 Million
2023 50.65% 11.81% 0.53x 8.14x AU$1.13 Million
2024 126.98% 14.59% 0.64x 13.60x AU$1.70 Million
2025 78.86% 13.35% 0.73x 8.15x AU$1.65 Million

Industry Comparison

This section compares Cryosite Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $177,089,396
  • Average return on equity (ROE) among peers: -45.51%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Cryosite Ltd (CTE) AU$2.39 Million -25.46% 7.15x $5.03 Million
Australian Clinical Labs Ltd (ACL) $68.99 Million 59.80% 4.31x $217.50 Million
Bcal Diagnostics Ltd (BDX) $6.22 Million -116.40% 0.59x $10.33 Million
Capitol Health Ltd (CAJ) $144.04 Million 0.60% 0.82x $222.66 Million
Genetic Signatures Ltd (GSS) $16.18 Million -10.68% 0.02x $8.20 Million
Healius Ltd (HLS) $1.04 Billion -62.05% 1.87x $208.81 Million
Inoviq Ltd (IIQ) $2.83 Million -115.42% 0.16x $23.33 Million
Microba Life Sciences Ltd (MAP) $32.49 Million -45.98% 0.46x $10.42 Million
Monash Ivf Group Ltd (MVF) $268.44 Million 9.37% 0.33x $116.82 Million
Pacific Edge Ltd (PEB) $13.91 Million -128.81% 0.19x $89.67 Million